- Home
- SCPH vs VSTM Comparison
SCPH vs VSTM Comparison
Compare SCPH & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- VSTM
- Stock Information
- Founded
- SCPH 2013
- VSTM 2010
- Country
- SCPH United States
- VSTM United States
- Employees
- SCPH N/A
- VSTM N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- VSTM Health Care
- Exchange
- SCPH Nasdaq
- VSTM Nasdaq
- Market Cap
- SCPH 274.7M
- VSTM 239.9M
- IPO Year
- SCPH 2017
- VSTM 2012
- Fundamental
- Price
- SCPH $3.26
- VSTM $4.22
- Analyst Decision
- SCPH Strong Buy
- VSTM Strong Buy
- Analyst Count
- SCPH 2
- VSTM 8
- Target Price
- SCPH $15.00
- VSTM $12.00
- AVG Volume (30 Days)
- SCPH 544.0K
- VSTM 1.1M
- Earning Date
- SCPH 11-13-2024
- VSTM 11-06-2024
- Dividend Yield
- SCPH N/A
- VSTM N/A
- EPS Growth
- SCPH N/A
- VSTM N/A
- EPS
- SCPH N/A
- VSTM N/A
- Revenue
- SCPH $30,278,000.00
- VSTM $10,000,000.00
- Revenue This Year
- SCPH $174.12
- VSTM N/A
- Revenue Next Year
- SCPH $133.41
- VSTM $53.90
- P/E Ratio
- SCPH N/A
- VSTM N/A
- Revenue Growth
- SCPH 303.87
- VSTM N/A
- 52 Week Low
- SCPH $3.08
- VSTM $2.10
- 52 Week High
- SCPH $6.71
- VSTM $14.22
- Technical
- Relative Strength Index (RSI)
- SCPH 43.13
- VSTM 47.50
- Support Level
- SCPH $3.11
- VSTM $4.18
- Resistance Level
- SCPH $3.67
- VSTM $4.85
- Average True Range (ATR)
- SCPH 0.21
- VSTM 0.42
- MACD
- SCPH 0.01
- VSTM -0.14
- Stochastic Oscillator
- SCPH 31.54
- VSTM 10.70
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.